Key Insights

Highlights

Success Rate

93% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

6.1%

2 terminated out of 33 trials

Success Rate

92.6%

+6.1% vs benchmark

Late-Stage Pipeline

45%

15 trials in Phase 3/4

Results Transparency

28%

7 of 25 completed with results

Key Signals

7 with results93% success

Data Visualizations

Phase Distribution

25Total
Not Applicable (4)
P 1 (2)
P 2 (4)
P 3 (14)
P 4 (1)

Trial Status

Completed25
Unknown5
Terminated2
Active Not Recruiting1

Trial Success Rate

92.6%

Benchmark: 86.5%

Based on 25 completed trials

Clinical Trials (33)

Showing 20 of 20 trials
NCT03553563Phase 3Completed

A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer

NCT04702542Not ApplicableActive Not Recruiting

To Develop Methods for the Rehabilitation of Chronic Gastroduodenal Pathology in Children.

NCT05579444Terminated

Systems Biology of Gastrointestinal and Related Diseases

NCT05010954Phase 3CompletedPrimary

Efficacy and Safety of LXI-15028 Comparing With Lansoprazole in the Treatment of Duodenal Ulcer

NCT05208268Completed

A Study of Pariet to Prevent Gastric and Duodenal Ulcer Associated With Low-aspirin in Korean Participants With a History of Gastric and Duodenal Ulcer

NCT00132171Phase 3Completed

Helicobacter Pylori Eradication With a New Sequential Treatment

NCT03050359Phase 3CompletedPrimary

Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection

NCT01729182Completed

Nexium Capsules LDA Specific Clinical Experience Investigation

NCT01562600Completed

Nexium Capsules Non-steroidal Anti-inflammatory Drug (NSAID) Specific Clinical Experience Investigation

NCT03057171Unknown

A Study on the Gastrointestinal Disease and Helicobacter Pylori Controlled Long Non-coding RNA

NCT02423187Completed

Rabeprazole Specific Clinical Experience Investigation for the Long-term Combination Therapy With Low-dose Aspirin

NCT02847455Phase 2CompletedPrimary

Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients

NCT00543868Phase 2Completed

MK0782 + Low-Dose Aspirin 7-Day Erosion Endoscopy Study (0782-001)

NCT01435525Completed

Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation

NCT01568398Phase 3Completed

A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin Therapy

NCT01568385Phase 3Completed

A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) Therapy

NCT01964131Phase 1Completed

BE Study Between a Capsule and a Sachet Formulation of D961H by Pharmacodynamics in Japanese Healthy Male Subjects

NCT01199536CompletedPrimary

Helicobacter Pylori Eradication Treatment in Patients With Duodenal Ulcers

NCT01452724Phase 3CompletedPrimary

Efficacy and Safety of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Duodenal Ulcer

NCT00595517Phase 3Completed

Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer

Scroll to load more

Research Network

Activity Timeline